Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide

COVID-19 induces a proinflammatory environment that is stronger in patients requiring intensive care. The cytokine components of this environment may determine efficacy or otherwise of glucocorticoid therapy. The immunity modulators, the aryl hydrocarbon receptor (AhR) and the nuclear NAD(+)-consumi...

Descripción completa

Detalles Bibliográficos
Autor principal: Badawy, Abdulla A.-B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Portland Press Ltd. 2020
Materias:
Cell Death & Injury
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601349/
https://www.ncbi.nlm.nih.gov/pubmed/33063092
http://dx.doi.org/10.1042/BSR20202856

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7601349/
https://www.ncbi.nlm.nih.gov/pubmed/33063092
http://dx.doi.org/10.1042/BSR20202856

Ejemplares similares